0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Biologics Market Forecasts 2018 to 2024
Published Date: April 2019
|
Report Code: INFO-Othe-047
Home | Market Reports | Business & Industrial | Pharmaceuticals & Biotech
Global Biologics Market Forecasts 2018 to 2024

Global Biologics Market Forecasts 2018 to 2024

Code: INFO-Othe-047
Report
April 2019
121 Pages
Infoholic Research
Region: Asia Pacific, Europe, Global, North America,
Description
Table of Content
Tables & Figures

Global Biologics Market – Drivers, Opportunities, Trends, and Forecasts: 2018–2024
Overview: Biologics drugs are complex molecules that are manufactured from living organisms or components of living organisms. Biologics include a wide variety of products derived from human, animal, or microorganisms by using biotechnological processes. Many biologics are produced using recombinant DNA technology. They are sometimes referred to as biopharmaceuticals or biological drugs. Various types of biologic drugs include monoclonal antibody, recombinant proteins/hormones, vaccines, cell and gene therapy and others. These biologics may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system. Biologics are sometimes referred as referred to as biologic response modifiers, as they change the manner of operation of natural biologic intracellular and cellular actions.
The market for biologics is driven by increasing incidence of disease across the globe, increasing number of biologics approvals and emergence of next generation biologics such as cell and gene therapy. Strong pipelined products and huge number of ongoing clinical trials are providing market growth oppurtunity. Challenges associated with biologics production, high cost of the drug, increasing number of biologics going off patent and emergence of biosimilars are hampering market growth.
Market Analysis: The “Global Biologics market” is estimated to witness a CAGR of 9.9% during the forecast period 2018–2024. The global market is analyzed based on three segments – Product, Application and regions.
Regional Analysis: The regions covered in the report are the North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is the major shareholder in the global biologics market, followed by Europe. North America dominates the biologics market due to increasing product approvals, increasing demand for the product to treat various disease conditions, and presence of established players in this region. Asia-Pacific region is expected to have the fastest growth rate during the forecasted period due to increasing research activities, flexible regulatory environment for clinical trials, growing awareness about biopharmaceutical therapeutics, and rising healthcare expenditure.
Product Analysis: The market by product is segmented into monoclonal antibodies, recombinant proteins/hormones, vaccines, cell and gene therapy and others. Monoclonal antibodies occupied major market share of global biologics market in 2017 and cell and gene therapy is expected to grow at high CAGR during the forecasted period. Wide application of monoclonal antibodies in treatment of various diseases makes this segment, a major shareholder of biologics products market.
Application Analysis: The market by application is segmented into cancer, infectious disease, immunological disorders, hematological disorders, cardiovascular disease and others. Among various application, cancer occupied the largest share in 2017 and is expected to grow at fastest rate during the forecasted period. Growing elderly population, changing lifestyle, increasing disease prevalence makes cancer, the fastest growing application segment during the forecasted period.
Key Players: F. Hoffmann-La Roche, Amgen, Inc., Sanofi S.A., Novo Nordisk A/S, Johnson and Johnson, AbbVie, Inc., Novartis AG, GlaxoSmithKline plc, Bristol-Myers Squibb, Merck & Co., Eli Lilly & Company Ltd., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company and other predominate and niche players.
Competitive Analysis: Currently cancer segment dominates the global biologics segment. Biologics are entering new therapeutic areas such as, asthma and allergy where they are not present historically. The key market players are taking the advantage of strategic deals and product approvals to increase their share in the market. For instance, in September 2017, GSK and AbCellera Biologics, Inc. entered an antibody discovery research collaboration, for the discovery of monoclonal antibodies against an undisclosed membrane protein target. In August 2017, Novartis received first FDA approval from FDA for CAR-T cell therapy, Kymriah to treat patients with B-cell precursor acute lymphoblastic leukemia (ALL) and in May 2018, Novartis received second FDA approval for Kymriah to treat patients with B-cell lymphoma.
Benefits: The report provides complete details about the usage and adoption rate of biologics in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Table of Contents


1 Industry Outlook 10
1.1 Industry Overview 10
1.2 Industry Trends 11
1.2.1 R&D pipeline in pharmaceutical industry 11
1.2.2 Top pharma drugs by sales in 2017 ($Million) 13
2 Report Outline 16
2.1 Report Scope 16
2.2 Report Summary 16
2.3 Research Methodology 17
2.4 Report Assumptions 17
3 Market Snapshot 19
3.1 Market Definition – Infoholic Research 19
3.2 Biologics patent expiration in US and Europe (2010-2020) 19
3.3 Segmented Addressable Market (SAM) 19
3.4 Trends of the biologics market 20
3.5 Related Markets 21
3.5.1 Over the counter drugs 21
3.5.2 Orphan drugs 22
3.5.3 Human Insulin 23
4 Market Outlook 25
4.1 Market segmentation 25
4.2 PEST Analysis 26
4.3 Porter 5(Five) Forces 27
5 Market Characteristics 28
5.1 DRO – Global Biologics Market Dynamics 28
5.1.1 Drivers 28
5.1.1.1 Growing incidence of disease across the globe 28
5.1.1.2 Increasing number of biologics approvals 29
5.1.2 Opportunities 30
5.1.2.1 Strong portfolio of product pipeline and huge number of ongoing clinical trials 30
5.1.2.2 Increasing opportunities in emerging markets 31
5.1.3 Restraints 32
5.1.3.1 Challenges associated with biologics production 32
5.1.3.2 Increasing number of biologics going off patent and emergence of biosimilars 33
5.2 DRO – Impact Analysis 33
5.3 Key Stakeholders 35
6 Products: Market Size & Analysis 36
6.1 Overview 36
6.2 Monoclonal antibodies 37
6.3 Recombinant proteins/Hormones 39
6.4 Vaccines 40
6.5 Cell and Gene Therapy 42
6.6 Others 43
7 Applications: Market Size & Analysis 45
7.1 Overview 45
7.2 Cancer 46
7.3 Immunological disorders 46
7.4 Infectious disease 47
7.5 Hematologic disorders 47
7.6 Cardiovascular disease 48
7.7 Others 48
8 Regions: Market Size and Analysis 49
8.1 Overview 49
8.2 North America 50
8.2.1 US 50
8.2.2 Canada 51
8.3 Europe 51
8.3.1 UK 52
8.3.2 Germany 53
8.3.3 France 53
8.3.4 Spain 53
8.4 Asia Pacific 54
8.4.1 India 54
8.4.2 China 55
8.4.3 Japan 55
8.5 Rest of the World 55
9 Competitive Landscape 57
9.1 Overview 57
10 Vendor Profiles 60
10.1 F. Hoffmann-La Roche 60
10.1.1 Overview 60
10.1.2 Business Unit 63
10.1.3 Geographic Presence 63
10.1.4 Business Focus 64
10.1.5 SWOT Analysis 64
10.1.6 Business Strategy 65
10.2 Sanofi S.A. 66
10.2.1 Overview 66
10.2.2 Business Units 70
10.2.3 Geographic Presence 71
10.2.4 Business Focus 71
10.2.5 SWOT Analysis 72
10.2.6 Business Strategies 72
10.3 Amgen Inc. 73
10.3.1 Overview 73
10.3.2 Geographic Presence 77
10.3.3 Business Focus 77
10.3.4 SWOT Analysis 79
10.3.5 Business Strategies 80
10.4 Novo Nordisk A/S 81
10.4.1 Overview 81
10.4.2 Business Units 84
10.4.3 Geographic Presence 85
10.4.4 Business Focus 85
10.4.5 SWOT Analysis 86
10.4.6 Business Strategies 86
10.5 AbbVie Inc. 87
10.5.1 Overview 87
10.5.2 Geographic Presence 90
10.5.3 Business Focus 90
10.5.4 SWOT Analysis 91
10.5.5 Business Strategies 91
10.6 Johnson & Johnson 92
10.6.1 Overview 92
10.6.2 Business Units 96
10.6.3 Geographic Revenue 96
10.6.4 Business Focus 97
10.6.5 SWOT Analysis 98
10.6.6 Business Strategies 98
10.7 Novartis AG 99
10.7.1 Overview 99
10.7.2 Business Units 102
10.7.3 Geographic Revenue 103
10.7.4 Business Focus 104
10.7.5 SWOT Analysis 104
10.7.6 Business Strategies 105
11 Companies to Watch for 106
11.1 Bristol-Myers Squibb 106
11.1.1 Overview 106
11.2 GlaxoSmithKline plc 108
11.2.1 Overview 108
11.3 Merck & Co. 110
11.3.1 Overview 110
11.4 Eli Lilly and Company Ltd. 111
11.4.1 Overview 111
11.5 Teva Pharmaceutical Industries Ltd. 113
11.5.1 Overview 113
11.6 AstraZeneca PLC 114
11.6.1 Overview 114
11.7 Takeda pharmaceuticals 117
11.7.1 Overview 117
Annexure 120
 Acronyms 120

List of Tables

TABLE 1 PHARMA DRUGS BY SALES, 2017 13
TABLE 2 GLOBAL BIOLOGICS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION) 49
TABLE 3 OTHER PROMINENT VENDORS OF BIOLOGICS MARKET 59
TABLE 4 F. HOFFMANN-LA ROCHE: OFFERINGS 60
TABLE 5 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 60
TABLE 6 SANOFI.: OFFERINGS 66
TABLE 7 SANOFI: RECENT DEVELOPMENTS 67
TABLE 8 AMGEN INC.: OFFERINGS 73
TABLE 9 AMGEN INC.: RECENT DEVELOPMENTS 74
TABLE 10 NOVO NORDISK A/S: OFFERINGS 81
TABLE 11 NOVO NORDISK A/S: RECENT DEVELOPMENTS 82
TABLE 12 ABBVIE INC.: OFFERINGS 88
TABLE 13 ABBVIE INC: RECENT DEVELOPMENTS 88
TABLE 14 JOHNSON & JOHNSON: PRODUCT OFFERINGS 92
TABLE 15 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 93
TABLE 16 NOVARTIS AG: PRODUCT OFFERINGS 99
TABLE 17 NOVARTIS AG: RECENT DEVELOPMENTS 100
TABLE 18 NOVARTIS AG: OVERVIEW SNAPSHOT 102
TABLE 19 BRISTOL-MYERS SQUIBB: SNAPSHOT 106
TABLE 20 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENTS 107
TABLE 21 GLAXOSMITHKLINE PLC.: OVERVIEW 108
TABLE 22 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 109
TABLE 23 MERCK & CO: OVERVIEW 110
TABLE 24 MERCK & CO: RECENT DEVELOPMENTS 110
TABLE 25 ELI LILLY AND COMPANY: SNAPSHOT 112
TABLE 26 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS 112
TABLE 27 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OVERVIEW 113
TABLE 28 TEVA PHARMACEUTICAL: RECENT DEVELOPMENTS 113
TABLE 29 ASTRAZENECA PLC: SNAPSHOT 115
TABLE 30 ASTRAZENECA PLC: RECENT DEVELOPMENTS 115
TABLE 31 TAKEDA PHARMACEUTICALS: SNAPSHOT 117
TABLE 32 TAKEDA PHARMACEUTICALS: RECENT DEVELOPMENTS 118

List of Charts

CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016) 11
CHART 2 PHARMACEUTICAL MOLECULLES IN DEVELOPMENT FOR NON-COMMUNICABLE DISEASES (NCDS) 12
CHART 3 R&D INVESTMENT BY TOP 10 COMPANIES ($BN) 12
CHART 4 PHARMACEUTICAL DRUGS BY SALES, 2017 14
CHART 5 RESEARCH METHODOLOGY OF GLOBAL BIOLOGICS MARKET 17
CHART 6 GLOBAL BIOLOGICS MARKET REVENUE, 2017–2024 ($MILLION) 21
CHART 7 SEGMENTATION OF GLOBAL BIOLOGICS MARKET 25
CHART 8 PEST ANALYSIS OF GLOBAL BIOLOGICS MARKET 26
CHART 9 PORTER 5 FORCES ON GLOBAL BIOLOGICS MARKET 27
CHART 10 DRO – IMPACT ANALYSIS OF GLOBAL BIOLOGICS MARKET 33
CHART 11 KEY STAKEHOLDERS 35
CHART 12 GLOBAL BIOLOGICS BY PRODUCT SEGMENTATION, 2017 (%) 36
CHART 13 GLOBAL MONOCLONAL ANTOBODY MARKET FORECAST, 2017–2024 ($MILLION) 38
CHART 14 GLOBAL RECOMBINANT PROTEIN/HORMONES MARKET FORECAST, 2017–2024 ($MILLION) 40
CHART 15 GLOBAL VACCINES MARKET FORECAST, 2017–2024 ($MILLION) 41
CHART 16 GLOBAL CELL AND GENE THERAPY MARKET FORECAST, 2017–2024 ($MILLION) 43
CHART 17 GLOBAL CELL AND GENE THERAPY MARKET FORECAST, 2017–2024 ($MILLION) 44
CHART 18 GLOBAL BIOLOGICS MARKET BY APPLICATION SEGMENTATION, 2017 (%) 45
CHART 19 GLOBAL BIOLOGICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%) 49
CHART 20 BIOLOGICS MARKET REVENUE IN NORTH AMERICA, 2017–2024 ($MILLION) 50
CHART 21 BIOLOGICS MARKET REVENUE IN EUROPE, 2017–2024 ($MILLION) 52
CHART 22 BIOLOGICS MARKET REVENUE IN ASIA PACIFIC, 2017–2024 ($MILLION) 54
CHART 23 BIOLOGICS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION) 56
CHART 24 F. HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT 62
CHART 25 F. HOFFMANN.LA ROCHE: BUSINESS UNITS 63
CHART 26 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE 63
CHART 27 F. HOFFMANN-LA ROCHE: SWOT ANALYSIS 64
CHART 28 SANOFI: OVERVIEW SNAPSHOT 69
CHART 29 SANOFI SA: BUSINESS UNITS 70
CHART 30 SANOFI SA: GEOGRAPHIC PRESENCE 71
CHART 31 SANOFI SA: SWOT ANALYSIS 72
CHART 32 AMGEN INC.: OVERVIEW SNAPSHOT 75
CHART 33 AMGEN INC.: GEOGRAPHIC PRESENCE 77
CHART 34 AMGEN INC: SWOT ANALYSIS 79
CHART 35 NOVO NORDISK: OVERVIEW SNAPSHOT 83
CHART 36 NOVO NORDISK: BUSINESS UNITS 84
CHART 37 NOVO NORDISK: GEOGRAPHIC PRESENCE 85
CHART 38 NOVO NORDISK A/S: SWOT ANALYSIS 86
CHART 39 ABBVIEE INC: OVERVIEW SNAPSHOT 89
CHART 40 ABBVIEE INC.: GEOGRAPHIC PRESENCE 90
CHART 41 ABBVIE INC.: SWOT ANALYSIS 91
CHART 42 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 95
CHART 43 JOHNSON & JOHNSON: BUSINESS UNITS 96
CHART 44 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 96
CHART 45 JOHNSON & JOHNSON: SWOT ANALYSIS 98
CHART 46 NOVARTIS AG: BUSINESS UNITS 102
CHART 47 NOVARTIS AG: GEOGRAPHIC REVENUE 103
CHART 48 NOVARTIS AG: SWOT ANALYSIS 104

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3500
This license allows only one user to access the PDF.

Electronic (PDF)
$4000
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$4500
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Lukasiewicz Research Network

RELATED REPORTS

Global and Japan qPCR Kits Market Insights Forecast to 2027
Global and Japan qPCR Kits Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-39Y7542
Wed Nov 24 00:00:00 UTC 2021

Add to Cart

Global and China Human ELISA Kits Market Insights Forecast to 2027
Global and China Human ELISA Kits Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-24Z7484
Wed Nov 24 00:00:00 UTC 2021

Add to Cart

Global and United States PCR Amplifier Market Insights Forecast to 2027
Global and United States PCR Amplifier Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-6W7895
Wed Nov 24 00:00:00 UTC 2021

Add to Cart

Global and China Porcine ELISA Kits Market Insights Forecast to 2027
Global and China Porcine ELISA Kits Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-37N7620
Wed Nov 24 00:00:00 UTC 2021

Add to Cart